Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Rose has reaffirmed a Buy rating on Globus Medical (NYSE:GMED) and increased the price target from $67 to $71, indicating a positive outlook on the company's stock.

December 20, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Rose maintains a Buy rating on Globus Medical and raises the price target from $67 to $71, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100